Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit?

Neurobiol Aging. 2008 Jun;29(6):795-811. doi: 10.1016/j.neurobiolaging.2007.01.010. Epub 2007 Feb 20.

Abstract

The last decade has revealed that the lifespan of an organism can be modulated by the signaling pathway that acts downstream of the insulin/insulin-like growth factor 1 receptors (IR/IGF1-R), indicating that there is a "program" that drives the process of aging. New results have now linked the same pathway to the neurogenic capacities of the aging brain, to neurotrophin signaling, and to the molecular pathogenesis of Alzheimer's disease. Therefore, a common signaling cascade now seems to link aging to age-associated pathologies of the brain, suggesting that pharmacologic approaches aimed at the modulation of this pathway can serve to delay the onset of age-associated disorders and improve the quality of life. Work from a wide range of fields performed with different approaches has already identified some of the signaling molecules that act downstream of IGF1-R, and has revealed that a delicate checkpoint exists to balance excessive growth/"immortality" and reduced growth/"senescence" of a cell. Future research will determine how far the connection goes and how much of it we can influence.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Aging / metabolism*
  • Alzheimer Disease / metabolism*
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Humans
  • Models, Neurological*
  • Nerve Growth Factors / metabolism*
  • Receptor, IGF Type 1 / metabolism*
  • Signal Transduction*

Substances

  • Amyloid beta-Peptides
  • Nerve Growth Factors
  • Receptor, IGF Type 1